Storm Therapeutics
7 known investors
STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.
Investors · 7
Competitors · 4
by search overlap
Alnylam12 shared keywordsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
Orna12 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Shape Therapeutics11 shared keywordsShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
Transcode Therapeutics10 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Companies competing with Storm Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Storm Therapeutics do?
- STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology. Its therapies address cancer, inflammation, viral infections, and CNS diseases.
- Who are Storm Therapeutics's investors?
- Storm Therapeutics's investors include Fast Track Initiative, M Ventures, Pfizer Venture Investments, Seroba Life Sciences, Taiho Ventures, LLC, UTokyo Innovation Platform Co. Ltd., Cambridge Innovation Capital.